Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints
Status:
Not yet recruiting
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
Posttraumatic stress disorder (PTSD) is frequently accompanied by difficulty concentrating,
poor memory, and inability to keep up with tasks, which negatively impacts a person's ability
to function at work and in relationships. Currently available treatments do not fully relieve
all symptoms. A published research report showed positive evidence that the stimulant
medication methylphenidate was beneficial in treating these problems. This study will
evaluate the ability of methylphenidate to treat PTSD and associated neurocognitive
complaints in Veterans. An innovative feature is the study's N-of-1 design. In this design,
every participant will move back and forth every 4-5 weeks between treatment with
methylphenidate and treatment with placebo, in random order and under double-blind
conditions, over a 20-week period. The investigators will compare the aggregated change in
PTSD and neurocognitive symptoms between periods of treatment with methylphenidate versus
placebo. Results will help clinicians to better choose the best treatment for Veterans living
with PTSD.